Search Results - "Rocconi, Rodney P."

ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling by Meng, Erhong, Mitra, Aparna, Tripathi, Kaushlendra, Finan, Michael A, Scalici, Jennifer, McClellan, Steve, Madeira da Silva, Luciana, Reed, Eddie, Shevde, Lalita A, Palle, Komaraiah, Rocconi, Rodney P

“…Aldehyde dehydrogenase (ALDH) expressing cells have been characterized as possessing stem cell-like properties. We evaluated ALDH+ ovarian cancer stem…”
Get full text

Corrigendum to “Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.” [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015] by Mani, Chinnadurai, Tripathi, Kaushlendra, Chaudhary, Sandeep, Somasagara, Ranganatha R., Rocconi, Rodney P., Crasto, Chiquito, Reedy, Mark, Athar, Mohammad, Palle, Komaraiah

Get full text

Validation of a venous thromboembolism risk assessment model in gynecologic oncology by Stroud, William, Whitworth, Jenny M, Miklic, Margaret, Schneider, Kellie E, Finan, Michael A, Scalici, Jennifer, Reed, Eddie, Bazzett-Matabele, Lisa, Straughn, J. Michael, Rocconi, Rodney P

“…Abstract Objectives Gynecologic oncology patients undergoing surgery are at an increased risk for venous thromboembolism (VTE). We attempted to validate a VTE…”
Get full text

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study by Konecny, Gottfried E, Dr, Finkler, Neil, Prof, Garcia, Agustin A, MD, Lorusso, Domenica, MD, Lee, Paula S, MD, Rocconi, Rodney P, MD, Fong, Peter C, MBBS, Squires, Matt, PhD, Mishra, Kaushal, PhD, Upalawanna, Allison, PharmD, Wang, Yongyu, MD, Kristeleit, Rebecca, MD

“…Summary Background Activating FGFR2 mutations are found in 10–16% of primary endometrial cancers and provide an opportunity for targeted therapy. We assessed…”
Get full text

Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition by Mani, Chinnadurai, Tripathi, Kaushlendra, Chaudhary, Sandeep, Somasagara, Ranganatha R., Rocconi, Rodney P., Crasto, Chiquito, Reedy, Mark, Athar, Mohammad, Palle, Komaraiah

“…Ovarian cancer (OC) is one of the most lethal type of cancer in women due to a lack of effective targeted therapies and high rates of treatment resistance and…”
Get full text

The limited utility of currently available venous thromboembolism risk assessment tools in gynecologic oncology patients by Pannucci, Christopher J., MD, MS, Rocconi, Rodney P., MD

Get full text

A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer by CASE, Ashley S, ROCCONI, Rodney P, STRAUGHN, J. Michael, CONNER, Michael, NOVAK, Lea, WENQUAN WANG, HUH, Warner K

“…To prospectively evaluate in a blinded fashion the accuracy of frozen section in endometrial cancer. Sixty patients with endometrial cancer or complex atypical…”
Get full text

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance by Oh, Jonathan, Barve, Minal, Senzer, Neil, Aaron, Phylicia, Manning, Luisa, Wallraven, Gladice, Bognar, Ernest, Stanbery, Laura, Horvath, Staci, Manley, Meghan, Nemunaitis, John, Walter, Adam, Rocconi, Rodney P.

Get full text

Racial health disparities in ovarian cancer: not just black and white by Srivastava, Sanjeev K, Ahmad, Aamir, Miree, Orlandric, Patel, Girijesh Kumar, Singh, Seema, Rocconi, Rodney P, Singh, Ajay P

“…Ovarian cancer (OC) is the most lethal gynecological malignancy, which disproportionately affects African American (AA) women. Lack of awareness and…”
Get full text

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer by Rocconi, Rodney P., Stanbery, Laura, Madeira da Silva, Luciana, Barrington, Robert A., Aaron, Phylicia, Manning, Luisa, Horvath, Staci, Wallraven, Gladice, Bognar, Ernest, Walter, Adam, Nemunaitis, John

“…Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and…”
Get full text

Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer – Navigating maintenance therapy for homologous recombinant proficient ovarian cancer by Goldsberry, Whitney N., Norquist, Barbara S., Rocconi, Rodney P., Modesitt, Susan C., Urban, Renata R.

“…The Society of Gynecologic Oncology (SGO) Journal Club is an open forum to review pertinent studies relevant to controversial topics in the management of…”
Get full text

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer by Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John

“…Background Broadened use of predictive molecular and phenotypic profiling amongst oncologists has facilitated optimal integration of targeted- and…”
Get full text

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer by Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John

Get full text

Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648] by Oh, Jonathan, Barve, Minal, Senzer, Neil, Aaron, Phylicia, Manning, Luisa, Wallraven, Gladice, Bognar, Ernest, Stanbery, Laura, Horvath, Staci, Manley, Meghan, Nemunaitis, John, Walter, Adam, Rocconi, Rodney P.

Get full text

A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer by Moore, Kathleen N, Herzog, Thomas J, Lewin, Sharyn, Giuntoli, Robert L, Armstrong, Deborah K, Rocconi, Rodney P, Spannuth, Whitney A, Gold, Michael A

“…Abstract Objective. Cisplatin-based combination therapy produces higher response rates and improved survival, in comparison to single-agent cisplatin in the…”
Get full text

MicroRNAs in gynecological cancers: Small molecules with big implications by Srivastava, Sanjeev K, Ahmad, Aamir, Zubair, Haseeb, Miree, Orlandric, Singh, Seema, Rocconi, Rodney P, Scalici, Jennifer, Singh, Ajay P

“…Abstract Gynecological cancers (GCs) are often diagnosed at advanced stages, limiting the efficacy of available therapeutic options. Thus, there remains an…”
Get full text

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer by Jones, Nathaniel L., Xiu, Joanne, Rocconi, Rodney P., Herzog, Thomas J., Winer, Ira S.

“…Increasing grade of endometrioid endometrial cancer (EEC) is associated with aggressive behavior and poor prognosis. The traditional classification system is…”
Get full text

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial by Rocconi, Rodney P, Grosen, Elizabeth A, Ghamande, Sharad A, Chan, John K, Barve, Minal A, Oh, Jonathan, Tewari, Devansu, Morris, Peter C, Stevens, Erin E, Bottsford-Miller, Justin N, Tang, Min, Aaron, Phylicia, Stanbery, Laura, Horvath, Staci, Wallraven, Gladice, Bognar, Ernest, Manning, Luisa, Nemunaitis, John, Shanahan, David, Slomovitz, Brian M, Herzog, Thomas J, Monk, Bradley J, Coleman, Robert L

“…Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from harvested tumour tissue, which specifically reduces expression of furin and downstream…”
Get full text

Impact of Travel Time on Health Care Costs and Resource Use by Phase of Care for Older Patients With Cancer by Rocque, Gabrielle B, Williams, Courtney P, Miller, Harold D, Azuero, Andres, Wheeler, Stephanie B, Pisu, Maria, Hull, Olivia, Rocconi, Rodney P, Kenzik, Kelly M

“…Many community cancer clinics closed between 2008 and 2016, with additional closings potentially expected. Limited data exist on the impact of travel time on…”
Get full text

CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival by Meng, Erhong, Long, Beverely, Sullivan, Paula, McClellan, Steve, Finan, Michael A., Reed, Eddie, Shevde, Lalita, Rocconi, Rodney P.

“…Cancer cells with the surface marker profile CD44+/CD24− have previously been described to possess cancer stem cell-like properties. This manuscript evaluates…”
Get full text